175
Participants
Start Date
June 12, 2017
Primary Completion Date
February 15, 2019
Study Completion Date
February 15, 2019
AR101 powder provided in capsules & sachets
Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
Placebo powder provided in capsules & sachets
Study product formulated to contain only inactive ingredients for use as defined in the protocol
Charité Universitaetsmedizin Berlin, Klinik für Pädiatrie mit Schwerpunkt Pneumologie und Immunologie, Berlin
Hospital General Universitario Gregorio Marañón, C/Manuel Esquerdo 46, Madrid
H. Infantil Universitario Niño Jesús, Servicio de Alergia, Madrid
Hospital Clinico San Carlos, Madrid Hospital Clinico San Carlos, Madrid
Unité de dermatologie Pédiatrique, Hôpital Pellegrin-Enfants, place Amélie Raba-Léon, Bordeaux
Azienda Ospedaliera di Padova, Padua
Hopital Saint Vincent de Paul, Service d'Allergologie, Lille
Paediatric Allergy and Pulmonology Center, Jeanne de Flandre Hospital, Lille University Hospital, Lille
University of Frankfurt, Klinik für Kinder- und Jugendmedizin, Pädiatrische Allergologie, Pneumologie und Mukoviszidose, Frankfurt am Main
Service d'Allergologie Nouvel Hôpital Civil Hôpitaux Univesitaires de Strasbourg, Strasbourg
UCC Dept. of Paediatrics and Child, Cork University Hospital, Cork
National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin
Sachsska Children and Youth Hospital, Stockholm
James Paget University Hospital, Gorleston-on-Sea
Guy & St Thomas' Hospital, NHS Foundation Trust, London
St. Mary's Hospital, London
Royal Manchester Children's Hospital, Manchester
University Hospitals Southampton Foundation NHS Trust, Southampton
Lead Sponsor
Aimmune Therapeutics, Inc.
INDUSTRY